Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Complete title: A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

Research Study Number ADVL1412
 
Principal Investigator Julie Park, MD
 
Phase I/II

Research Study Description

This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent) or do not respond to treatment (refractory). Monoclonal antibodies, such as nivolumab and ipilimumab, may block tumor growth in different ways by targeting certain cells. It is not yet known whether nivolumab works better alone or with ipilimumab in treating patients with recurrent or refractory solid tumors or sarcomas.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number ADVL1412
 
Contact Advanced Therapeutics Study Line
 
Telephone 206/987-2553
 
E-mail
 

Keywords: Hematologic Malignancies; Lymphoma, Hodgkin; Leukemia; Lymphoma; Lymphoproliferative Disorders; Melanoma; Pediatric Cancers, Miscellaneous; Neuroblastoma; Lymphoma, Non-Hodgkin (NHL); Neuroectodermal Tumors, Primitive (PNET); Sarcoma; Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms; Immunoproliferative Disorders; Neuroectodermal Tumors; Rhabdomyosarcoma; Sarcoma, Ewing; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial; Osteosarcoma; Neoplasms, Connective and Soft Tissue; Neoplasms, Bone Tissue; Immune System Diseases; Myosarcoma; Neoplasms, Muscle Tissue; Immunotherapy

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials